Aclaris Therapeutics
ACRS
71 hedge funds and large institutions have $33.4M invested in Aclaris Therapeutics in 2020 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 17 increasing their positions, 24 reducing their positions, and 16 closing their positions.
600% more call options, than puts
Call options by funds: $7K | Put options by funds: $1K
2.83% more ownership
Funds ownership: 74.45% → 77.28% (+2.8%)
10% less funds holding
Funds holding: 79 → 71 (-8)
25% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 16
29% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 24
43% less capital invested
Capital invested by funds: $58.2M → $33.4M (-$24.9M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$3.55M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
+$2.24M |
| 3 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$1.79M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.77M |
| 5 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$768K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$3.42M |
| 2 |
Man Group
London,
United Kingdom
|
-$1.64M |
| 3 |
Millennium Management
New York
|
-$533K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$210K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$165K |
ACRS Hedge Fund Activity: Q1 2020 in Review
71 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q1 2020, worth a combined $33.4M — down 43% from $58.2M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of ACRS and 12 opened new positions — a net loss of 4 holders — while 24 trimmed existing stakes and 17 added.
The largest buyer was Samsara BioCapital, opening a new position worth an estimated $3.55M. The largest seller was Morgan Stanley, cutting an estimated $3.42M.
- 71 institutional investors held Aclaris Therapeutics (ACRS) as of Q1 2020, down from 79 in Q4 2019.
- Funds reported $33.4M of Aclaris Therapeutics stock for Q1 2020, down 43% quarter-over-quarter.
- 12 funds opened new Aclaris Therapeutics positions in Q1 2020 and 16 closed out, a net change of -4 holders.
- The largest Aclaris Therapeutics buyer in Q1 2020 was Samsara BioCapital, an estimated $3.55M added.
- The largest Aclaris Therapeutics seller in Q1 2020 was Morgan Stanley, an estimated $3.42M sold.
Based on aggregated 13F filings for Q1 2020.